TMEM97 and Alzheimer disease: Hence, there remains an unmet clinical need to develop a suitable radioligand for neuroimaging of the σ2 receptor/TMEM97 in the human brain to investigate this target in AD progression, and to elucidate target engagement and the treatment mechanism of σ2 receptor-targeted drug candidates such as CT1812, in clinical trials.